Omnitura Therapeutics is a biopharmaceutical company commercializing a new class of Multivalent Immuno-Oncology Therapy designed to address the Fundamental Complexity of Cancer and Comorbid Chronic Diseases with a Systems Biology Approach.

Our initial disease focus in prostate cancer. Our lead drug candidate, Aneustat™, has an expected market launch in late 2023 or early 2024.

Aneustat™ is orally delivered and non-toxic. It has been shown to kill cancer cells at all stages of development through apoptosis without developing drug resistance. In combination with FDA approved standard-of-care drugs, Aneustat™ is expected to significantly improve efficacy and quality of life while avoiding or postponing the onset of drug resistance common to standard-of-care drugs.

Omnitura invites R&D collaboration, using Aneustat™ as the foundational drug to repurpose blockbuster legacy drugs and allow new patent protection.

To learn more about Omnitura Therapeutics please Contact Us.